Lilly Q3: Revenue $11.44B (+20% YoY); EPS $1.07/$1.18; FY revenue guidance raised to $45.4-$46.0B

ELI LILLY & Co

2024-Q3 EPS reported $6.83 revenue$31,509,900,000

Revenue $11.44B, up 20% YoY; excluding $1.42B prior-year olanzapine divestiture, revenue up 42%.
Reported EPS $1.07; non-GAAP EPS $1.18, both including $3.08 acquired IPR&D charges.
Mounjaro and Zepbound drove volume growth; non-incretin revenue up 17% ex-divestiture.
FY 2024 revenue guidance raised to $45.4-$46.0B; EPS guidance $12.05-$12.55 reported, $13.02-$13.52 non-GAAP.
Positive Phase 3 data for tirzepatide (94% diabetes risk reduction) and donanemab (reduced ARIA-E).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.